Market Cap : 158.29 B | Enterprise Value : 188.06 B | PE Ratio : 24.63 | PB Ratio : 4.85 |
---|
NYSE:BMY has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NYSE:BMY has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Bristol-Myers Squibb Co's revenue for the three months ended in Jun. 2022 was $11,887 Mil. Its revenue for the trailing twelve months (TTM) ended in Jun. 2022 was $47,144 Mil. Bristol-Myers Squibb Co's Revenue per Share for the three months ended in Jun. 2022 was $5.53. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2022 was $21.49.
During the past 12 months, the average Revenue per Share Growth Rate of Bristol-Myers Squibb Co was 9.60% per year. During the past 3 years, the average Revenue per Share Growth Rate was 14.40% per year. During the past 5 years, the average Revenue per Share Growth Rate was 12.80% per year. During the past 10 years, the average Revenue per Share Growth Rate was 6.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Bristol-Myers Squibb Co's highest 3-Year average Revenue per Share Growth Rate was 14.40% per year. The lowest was -8.40% per year. And the median was 3.90% per year.
The historical data trend for Bristol-Myers Squibb Co's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's Revenue distribution charts can be found below:
* The bar in red indicates where Bristol-Myers Squibb Co's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $47,144 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Thank you for viewing the detailed overview of Bristol-Myers Squibb Co's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Greenlees Sharon | officer: SVP & Controller | BRISTOL MYERS SQUIBB ROUTE 206 & PROVINCE LINE ROAD PRINCETON NJ 08543 |
Shanahan Karin | officer: EVP, Glob. Prod. Dev. & Supply | BRISTOL MYERS SQUIBB ROUTE 206 & PROVINCE LINE ROAD PRINCETON NJ 08543 |
Meyers Gregory Scott | officer: EVP, Chief Digital & Tech Off. | BRISTOL MYERS SQUIBB ROUTE 206 & PROVINCE LINE ROAD PRINCETON NJ 08543 |
Weese Michelle | officer: EVP, Corporate Affairs | BRISTOL MYERS SQUIBB ROUTE 206 & PROVINCE LINE ROAD PRINCETON NJ 08543 |
Hidalgo Medina Manuel | director | BRISTOL MYERS SQUIBB 430 E. 29TH STREET, 14TH FLOOR NEW YORK NY 10016 |
Rice Derica W | director | 1000 NICOLLET MALL TPS-3155 MINNEAPOLIS MN 55403 |
Price Paula A | director | ONE CVS DRIVE WOONSOCKET RI 02895 |
Mily Elizabeth | officer: EVP, Strategy & BD | BRISTOL-MYERS SQUIBB COMPANY ROUTE 206 & PROVENCE LINE ROAD PRINCETON NJ 08540 |
Metcalfe Kathryn | officer: EVP, Corporate Affairs | BRISTOL-MYERS SQUIBB COMPANY ROUTE 206 & PROVINCE LINE ROAD PRINCETON NJ 08543 |
Vessey Rupert | officer: Pres., Research & Early Dev. | C/O CELGENE CORPORATION 86 MORRIS AVENUE SUMMIT NJ 07901 |
Elkins David V | officer: EVP, Chief Financial Officer | C/O BECTON, DICKINSON AND COMPANY 1 BECTON DRIVE FRANKLIN LAKES NJ 07417 |
Bonney Michael W | director | 65 HAYDEN AVE LEXINGTON MA 02421 |
Yale Phyllis R | director | |
Ahmed Nadim | officer: President, Hematology | C/O CELGENE CORPORATION 86 MORRIS AVENUE SUMMIT NJ 07901 |
Haller Julia A | director | C/O CELGENE CORPORATION 86 MORRIS AVENUE SUMMIT NJ 07901 |
Other Sources
By Zacks 2022-03-29
By Zacks 2022-03-25
By Zacks 2022-03-25
By Fool 2022-03-30
By Zacks 2022-04-05
By Zacks 2022-04-05
By Zacks 2022-03-16
By Zacks 2022-03-16
By Zacks 2022-03-22
By Fool 2022-03-29
By Zacks 2022-03-29
By Fool 2022-03-31
By tipranks.com 2022-03-21
By Zacks 2022-03-16